LRRK2 and Parkinson disease: Azathioprine, another top-predicted immunosuppressant, is currently in a phase II PD clinical trial (AZA-PD) [72] and drug-target network analysis reveals that azathioprine may target multiple protein products of pdRGs, including LRRK2, BAG6, SNCA, HLA-C (Figure 4C).